ReviewClinical & translational immunology2023
Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non-infectious uveitis.
Review in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Putative mechanisms of ocular inflammation in syphilis.Journal of ophthalmic inflammation and infection · 2026Review
- Oxidative Stress and Uveitis: Molecular Mechanisms and Pathogenetic Role.Current issues in molecular biology · 2026Review
- Type III interferons attenuates Th1/Th17 cell pathogenicity and regulates retinal pigment epithelium cells via NLRP1/NLRP3 signaling axis in autoimmune uveitis.Genes & diseases · 2026Article
- Antiseptic Efficacy and Ocular Surface Toxicity of Povidone-Iodine and Chlorhexidine for Endophthalmitis Isolates.Investigative ophthalmology & visual science · 2026Article
- Blood-Ocular Barrier Dysfunction in Uveitis: A Bidirectional Model Linking Pathogenesis, Clinical Monitoring, and Therapeutic Opportunities.Medical sciences (Basel, Switzerland) · 2026Review
- Anti-Cell Staining Patterns in Juvenile Idiopathic Arthritis-Associated Uveitis: A Peek Behind the Curtain.Journal of clinical medicine · 2026Article
- Retinal microvascular changes in patients with ankylosing spondylitis receiving biologic therapy: a cross-sectional OCTA study.BMC ophthalmology · 2026Article
- Natural Products Targeting Immune Mechanisms in Ocular Inflammation: Uveitis and Dry Eye.Current issues in molecular biology · 2026Review
- Article
- Freeze-Dried Extracts ofPreventive nutrition and food science · 2026Article
- PANoptosis in diabetic retinopathy: immunological insights into mechanisms and translational therapies.Frontiers in immunology · 2026Review
- Associations between cMIND diet, mold exposure, and visual impairment among older adults in China: a national cross-sectional study.Frontiers in nutrition · 2026Article
- Advances of Intraocular Fluid for the Application and Treatment of Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Anti-inflammatory mechanisms ofInternational journal of ophthalmology · 2026Article
- Evaluation of Octenidine Dihydrochloride-Induced Cytotoxicity, Apoptosis, and Inflammatory Responses in Human Ocular Epithelial and Retinal Cells.Biomedicines · 2025Article
- AAV2.7m8 transduction of stage 2 human retinal organoids induces highly variable responses in innate and inflammatory gene expression and cytokine secretion.Experimental eye research · 2025Article
- Aquaporin-4 triggers inflammation in a murine endotoxin-induced uveitis (EIU) model.BMC ophthalmology · 2025Article
- Role of CD4Clinical and experimental medicine · 2025Review
- Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.Investigative ophthalmology & visual science · 2025Article
- Regenerative potential of immune cells after traumatic muscle injury.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterised by intraocular inflammation, non-infectious uveitis includes a large group of autoimmune and autoinflammatory diseases that either involve the eye alone or have both ocular and systemic manifestations. When non-infectious uveitis involves the posterior segment of the eye, specifically the retina, there is substantial risk of vision loss, often linked to breakdown of the inner blood-retinal barrier. This barrier is formed by non-fenestrated retinal vascular endothelial cells, reinforced by supporting cells that include pericytes, Müller cells and astrocytes. Across the published literature, a group of inflammatory cytokines stand out as prominent mediators of intraocular inflammation, with effects on the retinal endothelium that may contribute to breakdown of the inner blood-retinal barrier, namely tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, IL-17 and chemokine C-C motif ligand (CCL)2. This article reviews the function of each cytokine and discusses the evidence for their involvement in retinal endothelial barrier dysfunction in non-infectious uveitis, including basic laboratory investigations, studies of ocular fluids collected from patients with non-infectious uveitis, and results of clinical treatment trials. The review also outlines gaps in knowledge in this area. Understanding the disease processes at a molecular level can suggest treatment alternatives that are directed against appropriate biological targets to protect the posterior segment of eye and preserve vision in non-infectious uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.